Concord Biotech shares gain 6% after USFDA approval for Tofacitinib tablets

Concord Biotech's shares surged over 6% after receiving USFDA approval for its Tofacitinib Tablets in 5 mg and 10 mg strengths. This approval for rheumatoid arthritis and other conditions is expected to bolster its U.S. market presence and product portfolio, targeting a $500 million market opportunity.

Raccontata daeconomictimes.indiatimes.com